Wet Age-Related Macular Degeneration
VIDEO: ‘Excellent’ anatomic, vision control seen with 4D-150 at 24 weeks
PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Carl Danzig, MD, discusses a subset analysis of high-need patients receiving 4D-150 for wet age-related macular degeneration in the PRISM trial.
Healio’s top five ophthalmic business items
Catch up on Healio’s top five items in ophthalmic business from May.
nAMD and DME Management: Scaling Real-World Heights in Durability
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Curbside Consults: A Patient With Treatment-Resistant DME
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Curbside Consults: A Patient With Advanced, Treatment-Naive nAMD
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Opthea completes enrollment in two phase 3 trials of sozinibercept in wet AMD
Opthea has completed enrollment of its phase 3 COAST and ShORe trials, which will investigate the safety and efficacy of sozinibercept in combination with anti-VEGF-A therapy for wet age-related macular degeneration.
VIDEO: DAVIO 2 trial for wet AMD meets primary endpoint
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Ashkan M. Abbey, MD, shares topline data from the phase 2 DAVIO 2 trial investigating Duravyu for wet age-related macular degeneration.
VIDEO: Intravitreal implant for wet AMD shows positive results in three clinical trials
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Pravin U. Dugel, MD, of Ocular Therapeutix, overviews clinical results for Axpaxli, an axitinib implant for wet age-related macular degeneration.
VIDEO: Duravyu for wet AMD to enter phase 3 pivotal trials in second half of 2024
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Jay S. Duker, MD, of EyePoint Pharmaceuticals discusses lead product Duravyu.
Experts weigh current, future options for AMD management
The past 2 years have brought a decisive leap forward in the management of age-related macular degeneration.